Skip to main content
NCBI home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 2001 Oct;10(5):253–258. doi: 10.1080/09629350120093722

Cell adhesion molecules and hyaluronic acid as markers of inflammation, fibrosis and response to antiviral therapy in chronic hepatitis C patients.

E Granot 1, D Shouval 1, Y Ashur 1
PMCID: PMC1781718  PMID: 11759109

Abstract

OBJECTIVE: Cell adhesion molecules (intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1)) and hyaluronic acid, markers of inflammation and fibrosis were monitored in hepatitis C patients to determine whether changes in plasma levels, during antiviral treatment, can predict long-term response to therapy. METHODS: In 55 patients with chronic hepatitis C virus (HCV), 33 treated with interferon (IFN) and 22 treated with IFN + ribavirin, sera was collected prior to treatment, at 3 + 6 months of therapy and 6 months post-treatment. Levels of ICAM-1, VCAM-1 and hyaluronic acid were correlated with alanine aminotransferase levels, HCV-RNA-polymerase chain reaction status and histological fibrosis scoring. RESULTS: A decrease in ICAM-1 levels at 3 and 6 months of therapy, compared with pretreatment levels, was observed in responders to IFN + ribavirin therapy but this decrease in ICAM-1 levels was not evident following cessation of treatment. Hyaluronic acid levels, in both treatment groups, did not differ significantly between responders and non-responders. Hyaluronic acid levels did correlate, significantly, with degree of fibrosis whereas VCAM-1 levels were marginally increased only in patients with moderate (grade III) fibrosis. CONCLUSIONS: Monitoring of VCAM-1 and hyaluronic acid, during antiviral therapy, does not differentiate between responders and non-responders. A decrease in ICAM-1 levels during IFN + ribavirin treatment is associated with response to therapy, and its efficacy in predicting long-term response should be further substantiated.

Full Text

The Full Text of this article is available as a PDF (176.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacon B. R. Available options for treatment of interferon nonresponders. Am J Med. 1999 Dec 27;107(6B):67S–70S. doi: 10.1016/s0002-9343(99)00386-1. [DOI] [PubMed] [Google Scholar]
  2. Bagnasco M., Riccio A. M., Sinelli N., Campo N., Battifora M., Canonica G. W., Picciotto A. Serum intercellular adhesion molecule-1 and long-term response to IFN-alpha2b therapy in chronic hepatitis C. J Interferon Cytokine Res. 1998 Nov;18(11):963–966. doi: 10.1089/jir.1998.18.963. [DOI] [PubMed] [Google Scholar]
  3. Bloom S., Fleming K., Chapman R. Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis. Gut. 1995 Apr;36(4):604–609. doi: 10.1136/gut.36.4.604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Capra F., De Maria E., Lunardi C., Marchiori L., Mezzelani P., Beri R., Gabrielli G. B. Serum level of soluble intercellular adhesion molecule 1 in patients with chronic liver disease related to hepatitis C virus: A prognostic marker for responses to interferon treatment. J Infect Dis. 2000 Feb;181(2):425–431. doi: 10.1086/315265. [DOI] [PubMed] [Google Scholar]
  5. Engström-Laurent A., Löf L., Nyberg A., Schröder T. Increased serum levels of hyaluronate in liver disease. Hepatology. 1985 Jul-Aug;5(4):638–642. doi: 10.1002/hep.1840050420. [DOI] [PubMed] [Google Scholar]
  6. Gattoni A., Romano C., Cecere A., Caiazzo R., De Bellis A., Bizzarro A. Serum levels of soluble intercellular adhesion molecule 1 (sICAM-1) as a potential marker of disease activity and remission in patients with chronic hepatitis C. Panminerva Med. 1997 Dec;39(4):256–262. [PubMed] [Google Scholar]
  7. Kaplanski G., Farnarier C., Payan M. J., Bongrand P., Durand J. M. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Correlation with cytokine concentrations and liver inflammation and fibrosis. Dig Dis Sci. 1997 Nov;42(11):2277–2284. doi: 10.1023/a:1018818801824. [DOI] [PubMed] [Google Scholar]
  8. Knodell R. G., Ishak K. G., Black W. C., Chen T. S., Craig R., Kaplowitz N., Kiernan T. W., Wollman J. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981 Sep-Oct;1(5):431–435. doi: 10.1002/hep.1840010511. [DOI] [PubMed] [Google Scholar]
  9. Lang T., Krams S. M., Villanueva J. C., Cox K., So S., Martinez O. M. Differential patterns of circulating intercellular adhesion molecule-1 (cICAM-1) and vascular cell adhesion molecule-1 (cVCAM-1) during liver allograft rejection. Transplantation. 1995 Feb 27;59(4):584–589. [PubMed] [Google Scholar]
  10. Lo Iacono O., García-Monzón C., Almasio P., García-Buey L., Craxí A., Moreno-Otero R. Soluble adhesion molecules correlate with liver inflammation and fibrosis in chronic hepatitis C treated with interferon-alpha. Aliment Pharmacol Ther. 1998 Nov;12(11):1091–1099. doi: 10.1046/j.1365-2036.1998.00412.x. [DOI] [PubMed] [Google Scholar]
  11. Ninomiya T., Yoon S., Hayashi Y., Sugano M., Kumon Y., Seo Y., Shimizu K., Kasuga M. Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: histological evaluation by a modified histological activity index scoring system. J Gastroenterol Hepatol. 1998 Jan;13(1):68–74. doi: 10.1111/j.1440-1746.1998.tb00548.x. [DOI] [PubMed] [Google Scholar]
  12. Nishimura Y., Takei Y., Kawano S., Goto M., Nagano K., Tsuji S., Nagai H., Ohmae A., Fusamoto H., Kamada T. The F(ab')2 fragment of an anti-ICAM-1 monoclonal antibody attenuates liver injury after orthotopic liver transplantation. Transplantation. 1996 Jan 15;61(1):99–104. doi: 10.1097/00007890-199601150-00020. [DOI] [PubMed] [Google Scholar]
  13. Stål P., Broomé U., Scheynius A., Befrits R., Hultcrantz R. Kupffer cell iron overload induces intercellular adhesion molecule-1 expression on hepatocytes in genetic hemochromatosis. Hepatology. 1995 May;21(5):1308–1316. doi: 10.1002/hep.1840210514. [DOI] [PubMed] [Google Scholar]
  14. Ueno T., Inuzuka S., Torimura T., Tamaki S., Koh H., Kin M., Minetoma T., Kimura Y., Ohira H., Sata M. Serum hyaluronate reflects hepatic sinusoidal capillarization. Gastroenterology. 1993 Aug;105(2):475–481. doi: 10.1016/0016-5085(93)90722-o. [DOI] [PubMed] [Google Scholar]
  15. Wong V. S., Hughes V., Trull A., Wight D. G., Petrik J., Alexander G. J. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat. 1998 May;5(3):187–192. doi: 10.1046/j.1365-2893.1998.00100.x. [DOI] [PubMed] [Google Scholar]
  16. Yamada M., Fukuda Y., Koyama Y., Nakano I., Urano F., Katano Y., Hayakawa T. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. J Gastroenterol Hepatol. 1996 Jul;11(7):646–651. doi: 10.1111/j.1440-1746.1996.tb00308.x. [DOI] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES